Compositions comprising mixtures of semifluorinated alkanes
AssigneeNovaliq GmbH
InventorsBernhard Günther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer
Life of this patent
Estimating the term…
Abstract
The invention provides novel compositions comprising at least two or more semifluorinated alkanes. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue, such as for use in the treatment of keratoconjunctivitis sicca (dry eye) and/or meibomian gland dysfunction and symptoms associated therewith. The invention further provides kits comprising such compositions.
Claims24
A method for the treatment of a disease or disorder selected from keratoconjunctivitis sicca, Sjogren syndrome, lacrimal gland insufficiency, meibomian gland disease, and/or meibomian gland dysfunction, comprising administering to a patient in need thereof a composition comprising:
- one semifluorinated alkane or two or more different semifluorinated alkanes, wherein said composition is free of a therapeutically effective amount of any pharmaceutically active drug substance useful for ophthalmic treatment
- wherein the composition is topically administered to an eye or ophthalmic tissue.
A method for the treatment of a disease or disorder selected from keratoconjunctivitis sicca, Sjogren syndrome, lacrimal gland insufficiency, meibomian gland disease, and/or meibomian gland dysfunction, comprising administering to a patient in need thereof a composition comprising at least a first semifluorinated alkane of the formula F(CF2)n(CH2)mH, wherein n is an integer from the range of 3 to 8 and m is an integer from the range of 3 to 10, and
- a second semifluorinated alkane which is different than the first, wherein said composition is free of a therapeutically effective amount of any pharmaceutically active drug substance useful for ophthalmic treatment,
- wherein the composition is topically administered to an eye or ophthalmic tissue.
A method for the treatment of a disease or disorder selected from keratoconjunctivitis sicca, Sjogren syndrome, lacrimal gland insufficiency, meibomian gland disease, and/or meibomian gland dysfunction, comprising administering to a patient in need thereof a composition comprising at least two different semifluorinated alkanes, wherein the first semifluorinated alkane is selected from the group consisting of F(CF2)4(CH2)5H, F(CF2)4(CH2)6H, F(CF2)6(CH2)4H, F(CF2)6(CH2)6H, F(CF2)6(CH2)8H, and F(CF2)6(CH2)10H, and/or the second semifluorinated alkane is selected from the group consisting of F(CF2)8(CH2)10H and F(CF2)10(CH2)12H, wherein said composition is free of a therapeutically effective amount of any pharmaceutically active drug substance useful for ophthalmic treatment,
- wherein the composition is topically administered to an eye or ophthalmic tissue.
A method for the treatment of a disease or disorder selected from keratoconjunctivitis sicca, Sjogren syndrome, lacrimal gland insufficiency, meibomian gland disease, and/or meibomian gland dysfunction, comprising administering to a patient in need thereof a composition comprising one semifluorinated alkane or two or more different semifluorinated alkanes, wherein each semifluorinated alkane is independently a linear alkane or a branched alkane, some of whose hydrogen atoms have been replaced by fluorine, wherein said composition is free of a therapeutically effective amount of any pharmaceutically active drug substance useful for ophthalmic treatment,
- wherein the composition is topically administered to an eye or ophthalmic tissue.
Dependencies are inferred from the claim text.